Industrial Policy & Trade Monitor· 2666 actions· ✨ 89 recent

Russia's federal Industry Development Fund (FRP) disclosed a RUB 950 million (approx. USD 12 million) concessional loan under its "Development Projects" programme to biopharmaceutical company Nanolek LLC, financing purchase of high-tech equipment for Russia's first domestic human papillomavirus (HPV) vaccine production line. The facility, part of a RUB 7.5 billion total investment in the Orichevsky District of Kirov Region, opened 25-29 October 2025 and produces the "Tsegardeks" vaccine at an initial capacity of over 600,000 doses per year, rising to 3-3.5 million doses annually by 2027 with a planned second production line.

South Korea's National Assembly passed an amendment to the Korea Development Bank (KDB) Act on 2025-08-27 (428th session, 3rd plenary sitting, 164-1 with 164 votes in favour of 165 cast), raising KDB's statutory capital ceiling from KRW 30 trillion to KRW 45 trillion and creating a new "Advanced Strategic Industry Fund" inside KDB. The fund is capitalised at KRW 50 trillion or more over five years via low-rate government-guaranteed bonds and is earmarked for the ten officially designated advanced strategic industries (AI, semiconductors, bio/vaccines, defense, robotics, hydrogen, secondary batteries, displays, future mobility) via cheap loans and equity investment. KDB intends to use the fund as seed capital for a wider "National Growth Fund" that blends in private and pension capital to reach KRW 100 trillion+ in total strategic-industry financing over five years.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

On 22 January 2024, Brazil's National Council for Industrial Development (CNDI), reactivated by President Lula in 2023, launched Nova Indústria Brasil (NIB) — Brazil's first comprehensive national industrial policy since the 2011-2014 Plano Brasil Maior. The framework commits roughly R$300 billion (~USD 60 billion) in financing through 2026, distributed across loans, non-refundable grants and equity participations administered by BNDES (Brazilian Development Bank), Finep (Research and Projects Financing Company) and Embrapii (Brazilian Industrial Research and Innovation Company), with quantitative targets running to 2033. The R$300bn envelope combines R$106bn announced at the first CNDI meeting in July 2023 with R$194bn redirected from existing budget lines. NIB is structured around six "missions": (1) sustainable and digital agro-industrial chains, (2) health-industrial complex resilience (medicines, vaccines, devices), (3) urban infrastructure and green mobility, (4) digital transformation and Industry 4.0 including semiconductors, (5) bioeconomy and energy transition, and (6) defence, sovereignty and national-security technologies. Two presidential decrees signed the same day establish local-content preferences for New PAC public-procurement bids and create an Interministerial Public Procurement Commission. As of February 2025, BNDES had approved R$220bn in NIB-aligned operations, and the plan has anchored downstream sectoral programmes including Brasil Semicon, the Mover automotive programme and Mais Inovação.

Council Regulation (EU) 2022/2372, adopted 24 October 2022, establishes a binding framework empowering HERA (Health Emergency Preparedness and Response Authority) to activate emergency supply measures for crisis-relevant medical countermeasures — vaccines, therapeutics, PPE, medical devices, and in-vitro diagnostics — when a public health emergency at Union level is declared under Regulation (EU) 2022/2371. Emergency-mode powers include joint procurement on behalf of Member States, mandatory information requests to manufacturers on stockpiles and production capacity, accelerated R&D funding under the Emergency Research and Innovation Plan, and Union-level stockpile authority. This is the foundational binding instrument for the EU's post-COVID medical supply-chain resilience architecture; it is referenced by every subsequent EU pharma-resilience initiative including the Critical Medicines Act proposal (2025) and the 2025 MCM Strategy.

BIS amends the Export Administration Regulations (EAR) Commerce Control List to clarify the scope of ECCN 1C991 (vaccines, immunotoxins, and related medical products containing or derived from controlled biological agents) consistent with release and exclusion notes adopted at the June 2019 Australia Group (AG) Plenary Meeting. The rule adds clarifying language specifying which vaccines and medical products fall inside versus outside the ECCN 1C991 control perimeter, ensuring that routine vaccines produced by standard manufacturing methods are properly excluded. The changes align US controls with the Australia Group Common Control Lists without introducing new country-specific restrictions or license requirements.

The Investitionskontrollgesetz (InvKG, "Investment Control Act") is Austria's horizontal, statutory FDI screening regime. Published as Article 1 of the Federal Law BGBl. I Nr. 87/2020 on 24 July 2020 and entering into force on 25 July 2020, the Act replaced the previous narrow §§25a–25e Außenwirtschaftsgesetz 2011 (Foreign Trade Act) regime — under which fewer than 10 permits were issued from 2013 to mid-2020 — and transposes EU Regulation 2019/452 establishing a framework for the screening of foreign direct investments into the Union. The InvKG introduces mandatory ex-ante notification and approval of non-EU / non-EEA / non-Swiss acquisitions where the acquirer crosses any of the 10% / 25% / 50% voting-rights thresholds in an Austrian target operating in the critical sectors listed in Annex Part 1 (especially sensitive: defence, energy / water / telecoms critical infrastructure, dual-use technology, cybersecurity, AI, quantum technology, robotics, semiconductors, biotech, health, vaccines) and 25% / 50% in the sectors listed in Annex Part 2 (broader, including media, food-security, electronic communications infrastructure, financial infrastructure). Administered by the Bundesministerium für Arbeit und Wirtschaft (BMAW), with case decisions taken in coordination with the Komitee für Investitionskontrolle (inter-ministerial Investment Control Committee) and, where the case is escalated to the EU cooperation mechanism, the Commission and EU peer Member States. The InvKG is Austria's functional peer of US CFIUS / FIRRMA, UK NSI Act 2021, Germany AWG §§55–62, France Décret 2014-479 / R. 151-1 et seq., Italy Golden Power Decree, Netherlands Wet Vifo, Denmark investeringsscreeningsloven, and Belgium ISC. Sunset clause: originally limited to 30 June 2022 under §17(2) InvKG; permanently extended by BGBl. I Nr. 80/2022 of 14 July 2022.